Cell Source (Cell Source) EBIT : $-4.35 Mil (TTM As of Sep. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Cell Source EBIT?

Cell Source's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2023 was $-1.00 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2023 was $-4.35 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Cell Source's annualized ROC % for the quarter that ended in Sep. 2023 was -37.68%. Cell Source's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was %.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Cell Source's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was -45.75%.

Cell Source EBIT Historical Data

The historical data trend for Cell Source's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cell Source EBIT Chart

Cell Source Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

EBIT

Get a 7-Day Free Trial

-1.64

-4.17

-3.62

-4.11

-4.18

Cell Source Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
EBIT	Get a 7-Day Free Trial															-1.02	-1.07	-1.42	-0.86	-1.00

Competitive Comparison of Cell Source's EBIT

For the Biotechnology subindustry, Cell Source's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cell Source's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cell Source's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Cell Source's EV-to-EBIT falls into.

Cell Source EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.35 Mil.

Cell Source (OTCPK:CLCS) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Cell Source's annualized ROC % for the quarter that ended in Sep. 2023 is calculated as:

	ROC % (Q: Sep. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2023 )	+	Invested Capital (Q: Sep. 2023 ))	/ count )
=	-3.98 * ( 1 - 0% )	/	( (10.634	+	10.49)	/ 2 )
=	-3.98	/	10.562
=	-37.68 %

where

	Invested Capital		(Q: Jun. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.362	-	4.674	-	( 0.022	-	max(0, 15.308	-	0.362	+	0.022	))
=	10.634

	Invested Capital		(Q: Sep. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.248	-	5.789	-	( 0.003	-	max(0, 16.279	-	0.248	+	0.003	))
=	10.49

Note: The Operating Income data used here is four times the quarterly (Sep. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Cell Source's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Sep. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2023		Q: Sep. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-3.98	/	( ( (0 + max(-5.512, 0))	+	(0 + max(-6.56, 0)) )	/	2 )
=	-3.98	/	( ( 0	+	0 )	/	2 )
=	-3.98	/	0
=	%

where Working Capital is:

	Working Capital		(Q: Jun. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.34)	-	(4.674	+	0	+	1.178)
=	-5.512

	Working Capital		(Q: Sep. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.245)	-	(5.789	+	0	+	1.016)
=	-6.56

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Cell Source's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Sep. 2023 )
	=	-4.348	/	9.504
	=	-45.75 %

Cell Source EBIT Related Terms

Thank you for viewing the detailed overview of Cell Source's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Cell Source (Cell Source) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cell Source Inc (OTCPK:CLCS) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

57 West 57th Street, Suite 400, New York, NY, USA, 10019

Website

https://www.cell-source.com

Cell Source Inc is a biotechnology company focused on developing cell therapy treatments focused on immunotherapy. The company is involved with the development of proprietary immune system management technology. The company's subsidiary commercializes a suite of inventions relating to certain cancer treatments. Its other products include Anti-rejection Veto Cell tolerance therapy for both matched and mismatched allogeneic bone marrow transplantations and Anti-rejection Veto Cell tolerance therapy for both matched and mismatched organ transplantation.

Executives

George Verstraete	director	341 LAKEWOOD DRIVE, BLOOMFIELD HILLS MI 48304
Darlene Soave	director, 10 percent owner	341 LAKEWOOD DRIVE, BLOOMFIELD HILLS MI 48304
Yair Reisner	10 percent owner
Yoram Drucker	director	31 DOV SADAN ST., JERUSALEM L3 97844
Dennis M Brown	director	100 SAN MATEO DR, MENLO PARK CA 94025
Itamar Shimrat	director, officer: CEO and CFO	C/O CELL SOURCE, INC., 65 YIGAL ALON STREET, TEL AVIV L3 67433
David Zolty	director	C/O CELL SOURCE, INC., 65 YIGAL ALON STREET, TEL AVIV L3 67433
Benzion Abraham Friedman	director, 10 percent owner	C/O CELL SOURCE INC, 65 YIGALL ALON STREET, TEL AVIV L3 67433

Cell Source (Cell Source) Headlines

From GuruFocus

Pediatric Stem Cell Transplantation Expert and Industry Leader Dr. Joseph Rosenthal Joins Cell Source's Scientific Advisory Board

By PRNewswire PRNewswire • 02-25-2021